Hydrogel for reducing immune-related adverse events during immunotherapy
Year
2018
Project team
Jeremiah Johnson with Sachin Bhagchandani & Farrukh Vohidov
Cancer treatments
have adverse immune side effects
Hydrogel-based
technology controls delivery of therapies
Augmented efficacy
of combination therapeutics
Reducing side effects
Cancer treatments, especially new immunotherapies, but also traditional chemotherapy, have adverse immune side effects. To reduce the side effects of immunotherapy and other cancer treatments, we have developed a hydrogel-based technology that provides controlled intra-tumoral delivery of immunomodulators. This technology will be able to augment the therapeutic efficacy of combination immunotherapies as well as significantly reduce systemic toxicities